Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer

Asad A. Shah, Mark F. Berry, Ching Tzao, Mihir Gandhi, Mathias Worni, Ricardo Pietrobon, Thomas A. D'Amico

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: The optimal treatment strategy for patients with operable stage IIIA (N2) non-small cell lung cancer is uncertain. We performed a systematic review and meta-analysis to test the hypothesis that the addition of radiotherapy to induction chemotherapy prior to surgical resection does not improve survival compared with induction chemotherapy alone. Methods: A comprehensive search of PubMed for relevant studies comparing patients with stage IIIA (N2) non-small cell lung cancer undergoing resection after treatment with induction chemotherapy alone or induction chemoradiotherapy was conducted using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) standards. Hazard ratios were extracted from these studies to give pooled estimates of the effect of induction therapy on overall survival. Results: There were 7 studies that met criteria for analysis, including 1 randomized control trial, 1 phase II study, 3 retrospective reviews, and 2 published abstracts of randomized controlled trials. None of the studies demonstrated a survival benefit to adding induction radiation to induction chemotherapy versus induction chemotherapy alone. The meta-analysis performed on randomized studies (n = 156 patients) demonstrated no benefit in survival from adding radiation (hazard ratio 0.93, 95% confidence interval 0.54 to 1.62, p = 0.81), nor did the meta-analysis performed on retrospective studies (n = 183 patients, hazard ratio 0.77, 95% confidence interval 0.50 to 1.19, p = 0.24). Conclusions: Published evidence is sparse but does not support the use of radiation therapy in induction regimens for stage IIIA (N2). Given the potential disadvantages of adding radiation preoperatively, clinicians should consider using this treatment strategy only in the context of a clinical trial to allow better assessment of its effectiveness.

Original languageEnglish
Pages (from-to)1807-1812
Number of pages6
JournalAnnals of Thoracic Surgery
Volume93
Issue number6
DOIs
Publication statusPublished - Jun 2012
Externally publishedYes

Fingerprint

Induction Chemotherapy
Lung Neoplasms
Meta-Analysis
Survival
Radiation
Non-Small Cell Lung Carcinoma
Radiotherapy
Retrospective Studies
Confidence Intervals
Chemoradiotherapy
Therapeutics
PubMed
Randomized Controlled Trials
Clinical Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. / Shah, Asad A.; Berry, Mark F.; Tzao, Ching; Gandhi, Mihir; Worni, Mathias; Pietrobon, Ricardo; D'Amico, Thomas A.

In: Annals of Thoracic Surgery, Vol. 93, No. 6, 06.2012, p. 1807-1812.

Research output: Contribution to journalArticle

Shah, Asad A. ; Berry, Mark F. ; Tzao, Ching ; Gandhi, Mihir ; Worni, Mathias ; Pietrobon, Ricardo ; D'Amico, Thomas A. / Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. In: Annals of Thoracic Surgery. 2012 ; Vol. 93, No. 6. pp. 1807-1812.
@article{1ddf3d73e8ed4337815de3921afd9d6c,
title = "Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer",
abstract = "Background: The optimal treatment strategy for patients with operable stage IIIA (N2) non-small cell lung cancer is uncertain. We performed a systematic review and meta-analysis to test the hypothesis that the addition of radiotherapy to induction chemotherapy prior to surgical resection does not improve survival compared with induction chemotherapy alone. Methods: A comprehensive search of PubMed for relevant studies comparing patients with stage IIIA (N2) non-small cell lung cancer undergoing resection after treatment with induction chemotherapy alone or induction chemoradiotherapy was conducted using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) standards. Hazard ratios were extracted from these studies to give pooled estimates of the effect of induction therapy on overall survival. Results: There were 7 studies that met criteria for analysis, including 1 randomized control trial, 1 phase II study, 3 retrospective reviews, and 2 published abstracts of randomized controlled trials. None of the studies demonstrated a survival benefit to adding induction radiation to induction chemotherapy versus induction chemotherapy alone. The meta-analysis performed on randomized studies (n = 156 patients) demonstrated no benefit in survival from adding radiation (hazard ratio 0.93, 95{\%} confidence interval 0.54 to 1.62, p = 0.81), nor did the meta-analysis performed on retrospective studies (n = 183 patients, hazard ratio 0.77, 95{\%} confidence interval 0.50 to 1.19, p = 0.24). Conclusions: Published evidence is sparse but does not support the use of radiation therapy in induction regimens for stage IIIA (N2). Given the potential disadvantages of adding radiation preoperatively, clinicians should consider using this treatment strategy only in the context of a clinical trial to allow better assessment of its effectiveness.",
author = "Shah, {Asad A.} and Berry, {Mark F.} and Ching Tzao and Mihir Gandhi and Mathias Worni and Ricardo Pietrobon and D'Amico, {Thomas A.}",
year = "2012",
month = "6",
doi = "10.1016/j.athoracsur.2012.03.018",
language = "English",
volume = "93",
pages = "1807--1812",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer

AU - Shah, Asad A.

AU - Berry, Mark F.

AU - Tzao, Ching

AU - Gandhi, Mihir

AU - Worni, Mathias

AU - Pietrobon, Ricardo

AU - D'Amico, Thomas A.

PY - 2012/6

Y1 - 2012/6

N2 - Background: The optimal treatment strategy for patients with operable stage IIIA (N2) non-small cell lung cancer is uncertain. We performed a systematic review and meta-analysis to test the hypothesis that the addition of radiotherapy to induction chemotherapy prior to surgical resection does not improve survival compared with induction chemotherapy alone. Methods: A comprehensive search of PubMed for relevant studies comparing patients with stage IIIA (N2) non-small cell lung cancer undergoing resection after treatment with induction chemotherapy alone or induction chemoradiotherapy was conducted using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) standards. Hazard ratios were extracted from these studies to give pooled estimates of the effect of induction therapy on overall survival. Results: There were 7 studies that met criteria for analysis, including 1 randomized control trial, 1 phase II study, 3 retrospective reviews, and 2 published abstracts of randomized controlled trials. None of the studies demonstrated a survival benefit to adding induction radiation to induction chemotherapy versus induction chemotherapy alone. The meta-analysis performed on randomized studies (n = 156 patients) demonstrated no benefit in survival from adding radiation (hazard ratio 0.93, 95% confidence interval 0.54 to 1.62, p = 0.81), nor did the meta-analysis performed on retrospective studies (n = 183 patients, hazard ratio 0.77, 95% confidence interval 0.50 to 1.19, p = 0.24). Conclusions: Published evidence is sparse but does not support the use of radiation therapy in induction regimens for stage IIIA (N2). Given the potential disadvantages of adding radiation preoperatively, clinicians should consider using this treatment strategy only in the context of a clinical trial to allow better assessment of its effectiveness.

AB - Background: The optimal treatment strategy for patients with operable stage IIIA (N2) non-small cell lung cancer is uncertain. We performed a systematic review and meta-analysis to test the hypothesis that the addition of radiotherapy to induction chemotherapy prior to surgical resection does not improve survival compared with induction chemotherapy alone. Methods: A comprehensive search of PubMed for relevant studies comparing patients with stage IIIA (N2) non-small cell lung cancer undergoing resection after treatment with induction chemotherapy alone or induction chemoradiotherapy was conducted using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) standards. Hazard ratios were extracted from these studies to give pooled estimates of the effect of induction therapy on overall survival. Results: There were 7 studies that met criteria for analysis, including 1 randomized control trial, 1 phase II study, 3 retrospective reviews, and 2 published abstracts of randomized controlled trials. None of the studies demonstrated a survival benefit to adding induction radiation to induction chemotherapy versus induction chemotherapy alone. The meta-analysis performed on randomized studies (n = 156 patients) demonstrated no benefit in survival from adding radiation (hazard ratio 0.93, 95% confidence interval 0.54 to 1.62, p = 0.81), nor did the meta-analysis performed on retrospective studies (n = 183 patients, hazard ratio 0.77, 95% confidence interval 0.50 to 1.19, p = 0.24). Conclusions: Published evidence is sparse but does not support the use of radiation therapy in induction regimens for stage IIIA (N2). Given the potential disadvantages of adding radiation preoperatively, clinicians should consider using this treatment strategy only in the context of a clinical trial to allow better assessment of its effectiveness.

UR - http://www.scopus.com/inward/record.url?scp=84861634748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861634748&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2012.03.018

DO - 10.1016/j.athoracsur.2012.03.018

M3 - Article

VL - 93

SP - 1807

EP - 1812

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -